Teva Pharmaceuticals CR, s.r.o

What Teva Pharmaceuticals CR, s.r.o does

Teva Pharmaceuticals CR, s.r.o is the Czech commercial and manufacturing subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), operating in the Czech Republic since 1997 with three product pillars: generic medicines, specialty/biopharmaceuticals, and over-the-counter consumer health products. Through its portfolio of more than 350 medicines in the Czech market, it is the #1 player in Czech generics and delivers in excess of 20 million packages per year to Czech hospitals, pharmacies, and patients.

The company's operational backbone is the Opava manufacturing plant — a large-scale oral solid dose facility producing roughly 12 billion tablets and capsules annually, staffed by 1,700+ employees, and certified by FDA and EMA for export to 50+ international markets. The full value chain is integrated at this site, from active pharmaceutical ingredient processing through formulation, packaging, and EU Falsified Medicines Directive (FMD) serialization.

Teva CR earns revenue by selling generic and specialty medicines through Czech public reimbursement channels, hospital tenders, retail pharmacy distribution, and OTC retail channels; a portion of Opava's output is also transferred intra-group and sold to third parties in 50+ countries. Reported revenue in 2017 was approximately 2.5 billion CZK (~$100M), making it a mid-sized subsidiary within the global Teva group whose broader portfolio comprises ~1,800 molecules and ~16,000 products worldwide.

Name

Teva Pharmaceuticals CR, s.r.o

Legal name

Teva Pharmaceuticals CR, s.r.o.

Website

https://teva.cz

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

Teva Pharmaceuticals CR, s.r.o is the Czech subsidiary of Teva Pharmaceutical Industries, operating since 1997 as the #1 generics supplier in the Czech Republic across a 350+ SKU portfolio, with a 1,700-employee Opava plant producing 12 billion tablets annually for domestic use and 50+ export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Generic Tender & Government Supply Markets (HLAIABAM), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• Over-the-counter drugs
• Specialty biopharmaceuticals
• Pharmaceutical manufacturing

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Generic Medicines: Teva is the #1 on the Czech generic medicines market, supplying over 20 million packages of medicines annually to the Czech healthcare system. Generic drugs are bioequivalent to originator products at lower prices.
2. Specialty and Biopharmaceutical Products: Innovative specialty pharmaceuticals covering CNS disorders, respiratory diseases, oncology, and pain management. Includes original branded medicines and biosimilar products.
3. Over-the-Counter (OTC) Products: OTC medicines, dietary supplements, and cosmetic products sold without prescription in pharmacies. Brands include Hylak forte, Vibovit, Ambrobene, Stoptussin, Analergin, Sudocrem, Olfen, Orlistat, Novo-Passit, and others.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Teva Pharmaceuticals CR, s.r.o. manufactures, markets, and distributes a diversified pharmaceutical portfolio in the Czech Republic across three pillars: generic medicines (350+ products in the Czech portfolio), original and biopharmaceutical preparations for CNS, respiratory, oncology, and pain, and a broad OTC catalog (allergies, cough, throat, venous, digestive, fungal indications). The Opava manufacturing plant produces 12 billion tablets and hard gelatin capsules per year, which are distributed to over 50 international markets in addition to the Czech healthcare system.

Product overview

Teva Pharmaceuticals CR, s.r.o. is the Czech commercial and manufacturing subsidiary of Teva Pharmaceutical Industries Ltd., operating as a diversified pharmaceutical company with three core product pillars: (1) Generická léčiva (Generic Medicines) — a portfolio of more than 1,800 molecules manufactured in approximately 80 facilities producing 120 billion tablets and capsules annually, with top-3 positions in 40 global markets; (2) Originální a biofarmaceutické přípravky (Original and Biopharmaceutical Preparations) — innovative treatments for CNS disorders, respiratory diseases, oncology, and pain management; and (3) Volně prodejné léčivé přípravky (OTC Medicines) — a catalog of 36+ OTC products including Aescin Teva, Ambrobene (multiple strengths and forms), Analergin, Candibene, Ditustat, Dituzdin, Herpesin krém, Hylak forte, Jox, Laxygal, Stopangin, Stoptussin, Thymomel, and Tussin, spanning therapeutic areas such as allergies, cough, throat inflammation, venous disorders, cold sores, digestive disorders, constipation, and fungal infections. Supporting product lines include Doplňky stravy (dietary supplements) such as Vibovit Imunity, and Kosmetické přípravky (cosmetic products). The company also provides pharmacovigilance and patient safety services.

Differentiator

Problem solved

Functional benefit

Brands

• Hylak: OTC product - peroral solution for digestive health
• Vibovit
• Amb robene
• Analergin
• Stoptussin
• Sudocrem
• Novo-Passit
• Olfen
• Orlistat

Products and services

• Generic Medicines (Generická léčiva) Bioequivalent generic medicines covering nearly all therapeutic areas; the Czech portfolio includes more than 350 medicines and the global portfolio spans more than 1,800 molecules produced across approximately 80 manufacturing plants, with 120 billion tablets and capsules annually and top-3 positions in 40 markets. Teva is the #1 generic supplier in the Czech Republic with over 20 million packages delivered to Czech healthcare each year.
• Original and Biopharmaceutical Preparations (Originální a biofarmaceutické přípravky) Innovative branded specialty pharmaceuticals and biosimilars for central nervous system disorders (neurodegenerative diseases, migraine, headache, sleep), respiratory conditions (asthma, allergic rhinitis, COPD), oncology, and pain management, including innovative headache/migraine solutions and opioid pain medications. Includes reference products whose active substances and know-how are protected by patent.
• Over-the-Counter (OTC) Medicines OTC medicines available without prescription for the treatment of simple and short-term health conditions, including brands such as Aescin Teva (venous disorders), Ambrobene (multiple strengths and forms, cough/respiratory), Analergin and Analergin Neo (allergies), Candibene (antifungal), Ditustat and Dituzdin (cough), Herpesin (cold sores), Hylak forte (digestive disorders), Jox (throat), Laxygal (constipation), Stopangin (throat), Stoptussin (cough syrup, drops, tablets), Thymomel and Tussin (cough). Paid fully out-of-pocket by patients.
• Dietary Supplements (Doplňky stravy) Concentrated nutrient sources intended to supplement the normal diet; examples include Vibovit Imunity, a multivitamin jelly with 11 vitamins and minerals plus natural black elderberry flavor for children aged 3+. Not medicinal products; not intended to treat disease.
• Cosmetic Products (Kosmetické přípravky) Substances intended for contact with external parts of the human body (skin, hair, nails, lips, external genital organs) or teeth and oral mucosa, for cleaning, perfuming, changing appearance, protection, or body odor adjustment.
• Patient Safety / Pharmacovigilance Services Pharmacovigilance services monitoring, detecting, analyzing, and reporting potential safety risks related to the use of medicinal products, including signal detection, periodic safety update reports, risk management plans, and a detailed adverse event database for post-market surveillance.

Quantifiable outcome

• 12 billion tablets and hard gelatin capsules produced annually at Opava plant alone, distributed to over 50 markets
• +3 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Direct ReliefcoreStrategic or Co-development Partner · 13 March 2022Teva partnered with Direct Relief, a nonprofit humanitarian organization, to donate essential medicines worth over $6.7 million to Ukrainian refugees. The donation included 150,000 packages of 14 Teva products, 13 on the WHO essential medicines list, sent to Moldova for distribution at the Ukrainian border.
• Člověk v tísniminorStrategic or Co-development Partner · 13 March 2022Teva partnered with Czech humanitarian NGO Člověk v tísni to provide approximately 82,000 packages of hygiene products for Ukrainian infants and children affected by the humanitarian crisis.
• United HatzalahminorStrategic or Co-development Partner · 13 March 2022Teva donated 25,405 packages of antibiotics worth approximately $180,000 to United Hatzalah, an Israeli nonprofit emergency and humanitarian organization, for use in refugee camps and field hospitals in Romania on the Ukrainian border.
• Global HOPEcoreStrategic or Co-development Partner · 1 January 2021Teva expanded its partnership with Global HOPE to provide critical treatment for children with cancer and blood disorders in sub-Saharan Africa as part of access-to-medicines programs.
• HealintcoreStrategic or Co-development Partner · 5 September 2018Partnership with Healint, developer of the Migraine Buddy platform, to provide European migraine patients and their doctors with the latest independent, reliable medical information. Statistical data from the platform comes from patients who anonymously described their situation to improve awareness and research.
• Migraine Trust International Symposium (MTIS)minorGTM or Marketing Partner · 5 September 2018Teva collaborated with MTIS to create a series of online conversations with leading neurologists including Professor Peter J. Goadsby from King's College London. Content available on NeurologyBytes.com for healthcare professionals.
• NeurologyBytescoreGTM or Marketing Partner · 5 September 2018NeurologyBytes is a European healthcare professional portal created by Teva providing educational materials for neurologists and specialists, addressing the gap in reliable medical information online.
• DRG DigitalminorGTM or Marketing Partner · 1 January 2018DRG Digital provides data on how young physicians increasingly rely on online and external digital sources including professional websites, spending up to three hours daily on medical research online.
• Česká lékárnická komora (Czech Chamber of Pharmacists)coreStrategic or Co-development Partner · 1 January 2018Teva partnered with the Czech Chamber of Pharmacists for the 'Nebojte se zachránit život' (Don't Be Afraid to Save a Life) public education campaign on first aid for adults and children, held annually on World First Aid Day.

Scale indicators13 records

Recent moves7 records

Expansion highlights4 records

Emerging players

• Almirall: Almirall is a European specialty and dermatology-focused pharma with growing OTC exposure (e.g., recent franchise acquisitions), comparable to Teva CR's specialty/OTC pivot in CNS, respiratory and dermatology categories marketed through CEE pharmacy channels.

Broad incumbents

• Sandoz: Sandoz is the Novartis generics and biosimilars division with broad European scale; it competes with Teva CR on prescription generics, biosimilars and selected OTC lines, and is the most natural large-cap comparable for Teva's Czech and export generics franchise.

Regional players

• Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharma group with strong CEE/CIS presence, competing with Teva CR on generics and specialty in the region and offering a comparable CEE manufacturing-and-distribution model.
• Hikma Pharmaceuticals: Hikma is a generics and specialty pharma group with strong MENA and European operations, supplying hospitals and wholesalers with comparable generic injectables, oral solids and specialty products; less direct retail presence in Czech OTC but comparable manufacturing economics.
• EGIS Pharmaceuticals: EGIS is a Hungarian pharma manufacturer with CEE-wide generics and specialty coverage, supplying tenders, hospitals and pharmacies with overlapping molecules to Teva CR; highly comparable business model in CEE markets adjacent to Czech Republic.
• Polpharma: Polpharma is the largest Polish generics manufacturer with growing CEE footprint, comparable to Teva CR on generic prescription supply, OTC and manufacturing scale; competes primarily on regional tenders rather than directly in Czech retail.

Direct peers

• Stada Arzneimittel: Stada is a European-focused generics and OTC player that competes head-to-head with Teva CR in Czech generics and OTC categories (e.g., cough/cold, dermatology), and operates a similar pharma distributor-to-pharmacy go-to-market model across CEE.
• Viatris: Viatris (formed from Mylan and Upjohn) is a global generics powerhouse with significant CEE distribution, directly overlapping Teva CR on generic molecules, biosimilars and OTC portfolios supplied through the same pharmacy and hospital channels.
• Zentiva: Zentiva is a Prague-headquartered generics manufacturer with deep Czech and CEE heritage, directly competing with Teva CR for generic tenders, OTC shelf space and pharmacy channel share across the same therapeutic categories and the same Czech public reimbursement system.
• Krka: Krka is a Slovenian generic and specialty pharma company with a leading CEE presence, directly contesting Teva CR on tenders and hospital supply in the Czech Republic and neighboring markets with overlapping therapeutic coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/tevapharmeurope
• Facebookfacebook.com/teva.cz
• LinkedInlinkedin.com/company/teva-pharmaceuticals-cr-s-r-o

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teva Pharmaceuticals CR, s.r.o